Zimmer Biomet Holdings, Inc. ZBH
We take great care to ensure that the data presented and summarized in this overview for ZIMMER BIOMET HOLDINGS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ZBH
View all-
Vanguard Group Inc Valley Forge, PA23.3MShares$2.49 Billion0.05% of portfolio
-
Dodge & Cox San Francisco, CA17.1MShares$1.82 Billion1.12% of portfolio
-
Black Rock Inc. New York, NY16.8MShares$1.8 Billion0.04% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD14.6MShares$1.56 Billion0.18% of portfolio
-
State Street Corp Boston, MA9.08MShares$971 Million0.04% of portfolio
-
American Century Companies Inc Kansas City, MO6.54MShares$699 Million0.42% of portfolio
-
Primecap Management CO Pasadena, CA4.97MShares$531 Million0.4% of portfolio
-
Geode Capital Management, LLC Boston, MA4.88MShares$521 Million0.04% of portfolio
-
Invesco Ltd. Atlanta, GA4.36MShares$466 Million0.09% of portfolio
-
Van Eck Associates Corp3.74MShares$399 Million0.49% of portfolio
Latest Institutional Activity in ZBH
Top Purchases
Top Sells
About ZBH
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Insider Transactions at ZBH
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 10
2024
|
Suketu Upadhyay Exec. VP, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,097
-19.26%
|
$766,476
$108.48 P/Share
|
Nov 10
2024
|
Suketu Upadhyay Exec. VP, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,948
+30.21%
|
-
|
Jul 01
2024
|
Wilfred Van Zuilen Group Pres, EMEA |
SELL
Payment of exercise price or tax liability
|
Direct |
557
-5.68%
|
$59,599
$107.36 P/Share
|
Jul 01
2024
|
Wilfred Van Zuilen Group Pres, EMEA |
BUY
Exercise of conversion of derivative security
|
Direct |
2,633
+21.18%
|
-
|
Jun 01
2024
|
Paul A Stellato VP, Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
197
-12.48%
|
$22,458
$114.47 P/Share
|
Jun 01
2024
|
Paul A Stellato VP, Controller & CAO |
BUY
Exercise of conversion of derivative security
|
Direct |
627
+28.42%
|
-
|
May 31
2024
|
Sang Yi Group President, Asia Pacific |
SELL
Open market or private sale
|
Direct |
12,857
-70.72%
|
$1,465,698
$114.69 P/Share
|
Apr 01
2024
|
Lori Winkler SVP and CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
215
-6.05%
|
$27,950
$130.65 P/Share
|
Apr 01
2024
|
Lori Winkler SVP and CHRO |
BUY
Exercise of conversion of derivative security
|
Direct |
772
+17.86%
|
-
|
Mar 07
2024
|
Sang Yi Group President, Asia Pacific |
SELL
Open market or private sale
|
Direct |
1,705
-8.57%
|
$214,830
$126.86 P/Share
|
Mar 07
2024
|
Sang Yi Group President, Asia Pacific |
BUY
Exercise of conversion of derivative security
|
Direct |
1,705
+7.9%
|
$155,155
$91.53 P/Share
|
Mar 06
2024
|
Ivan Tornos President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,642
-17.42%
|
$705,250
$125.82 P/Share
|
Mar 06
2024
|
Ivan Tornos President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,270
+24.07%
|
-
|
Mar 06
2024
|
Suketu Upadhyay Exec. VP, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,919
-8.46%
|
$239,875
$125.82 P/Share
|
Mar 06
2024
|
Suketu Upadhyay Exec. VP, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,561
+16.74%
|
-
|
Mar 06
2024
|
Wilfred Van Zuilen Group Pres, EMEA |
SELL
Payment of exercise price or tax liability
|
Direct |
260
-3.5%
|
$32,500
$125.82 P/Share
|
Mar 06
2024
|
Wilfred Van Zuilen Group Pres, EMEA |
BUY
Exercise of conversion of derivative security
|
Direct |
2,163
+22.55%
|
-
|
Mar 06
2024
|
Lori Winkler SVP and CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
428
-13.35%
|
$53,500
$125.82 P/Share
|
Mar 06
2024
|
Lori Winkler SVP and CHRO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,757
+35.39%
|
-
|
Mar 06
2024
|
Sang Yi Group President, Asia Pacific |
BUY
Exercise of conversion of derivative security
|
Direct |
2,365
+11.51%
|
-
|
Last 12 Months Summary
Exercise of conversion of derivative security | 107K shares |
---|
Payment of exercise price or tax liability | 27.1K shares |
---|---|
Open market or private sale | 40.7K shares |